Terminology for anticoagulation and antiplatelet therapy in arterial thrombosis
| . | Term . | Abbreviation . | Meaning . |
|---|---|---|---|
| Combination therapy | Dual antiplatelet therapy | DAPT | Aspirin 81 mg + P2Y12 inhibitor |
| Dual antithrombotic therapy | DAT | Anticoagulation + one antiplatelet agent (commonly in patients with AF and CAD) | |
| Dual pathway inhibition | DPI | Very low-dose anticoagulation + antiplatelet agent(s) | |
| Triple antithrombotic therapy Triple therapy | TAT TT | Anticoagulation + 2 antiplatelet agents | |
| DOAC dosing | Standard-dose DOAC | — | Apixaban 5 mg BID Dabigatran 150 mg BID Dabigatran 220 mg daily Edoxaban 60 mg daily Rivaroxaban 20 mg daily |
| Reduced-dose DOAC* | — | Apixaban 2.5 mg BID† Rivaroxaban 15 mg daily‡ | |
| Low dose DOAC Prophylactic dose DOAC | — | Apixaban 2.5 mg BID Rivaroxaban 10 mg daily | |
| Very low-dose DOAC | — | Rivaroxaban 2.5 mg BID |
| . | Term . | Abbreviation . | Meaning . |
|---|---|---|---|
| Combination therapy | Dual antiplatelet therapy | DAPT | Aspirin 81 mg + P2Y12 inhibitor |
| Dual antithrombotic therapy | DAT | Anticoagulation + one antiplatelet agent (commonly in patients with AF and CAD) | |
| Dual pathway inhibition | DPI | Very low-dose anticoagulation + antiplatelet agent(s) | |
| Triple antithrombotic therapy Triple therapy | TAT TT | Anticoagulation + 2 antiplatelet agents | |
| DOAC dosing | Standard-dose DOAC | — | Apixaban 5 mg BID Dabigatran 150 mg BID Dabigatran 220 mg daily Edoxaban 60 mg daily Rivaroxaban 20 mg daily |
| Reduced-dose DOAC* | — | Apixaban 2.5 mg BID† Rivaroxaban 15 mg daily‡ | |
| Low dose DOAC Prophylactic dose DOAC | — | Apixaban 2.5 mg BID Rivaroxaban 10 mg daily | |
| Very low-dose DOAC | — | Rivaroxaban 2.5 mg BID |
Dosing regimens for patients with renal impairment, low body weight, and/or advanced age. See apixaban† and rivaroxaban‡ details.
Dosing for patients with AF who meet 2 of the following 3 criteria: creatinine ≥1.5 mg/dL, age ≥80 years, and weight ≤60 kg.
Dosing used in patients with AF with creatinine clearance ≤50 mL/min.
AF, atrial fibrillation; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; BID, twice daily.